BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Melim C, Jarak I, Veiga F, Figueiras A. The potential of micelleplexes as a therapeutic strategy for osteosarcoma disease. 3 Biotech 2020;10:147. [PMID: 32181109 DOI: 10.1007/s13205-020-2142-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 da Silva TN, de Lima EV, Barradas TN, Testa CG, Picciani PHS, Figueiredo CP, do Carmo FA, Clarke JR. Nanosystems for gene therapy targeting brain damage caused by viral infections. Mater Today Bio 2023;18:100525. [PMID: 36619201 DOI: 10.1016/j.mtbio.2022.100525] [Reference Citation Analysis]
2 Todosenko N, Yurova K, Khaziakhmatova O, Malashchenko V, Khlusov I, Litvinova L. Heparin and Heparin-Based Drug Delivery Systems: Pleiotropic Molecular Effects at Multiple Drug Resistance of Osteosarcoma and Immune Cells. Pharmaceutics 2022;14:2181. [DOI: 10.3390/pharmaceutics14102181] [Reference Citation Analysis]
3 Figueiras A, Domingues C, Jarak I, Santos AI, Parra A, Pais A, Alvarez-lorenzo C, Concheiro A, Kabanov A, Cabral H, Veiga F. New Advances in Biomedical Application of Polymeric Micelles. Pharmaceutics 2022;14:1700. [DOI: 10.3390/pharmaceutics14081700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Suleman A, Kondiah PPD, Mabrouk M, Choonara YE. The Application of 3D-Printing and Nanotechnology for the Targeted Treatment of Osteosarcoma. Front Mater 2021;8:668834. [DOI: 10.3389/fmats.2021.668834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hattinger CM, Patrizio MP, Fantoni L, Casotti C, Riganti C, Serra M. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers (Basel) 2021;13:2878. [PMID: 34207685 DOI: 10.3390/cancers13122878] [Cited by in Crossref: 20] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
6 Kratzer K, Getz LJ, Peterlini T, Masson JY, Dellaire G. Addressing the dark matter of gene therapy: technical and ethical barriers to clinical application. Hum Genet 2021. [PMID: 33834266 DOI: 10.1007/s00439-021-02272-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Liu L, Geng H, Mei C, Chen L. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis. Oxid Med Cell Longev 2021;2021:6661534. [PMID: 33859780 DOI: 10.1155/2021/6661534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 方 献. A Case Report of Hand Osteosarcoma. ACM 2021;11:5557-5562. [DOI: 10.12677/acm.2021.1111824] [Reference Citation Analysis]
9 Yan X, Yang C, Hu W, Chen T, Wang Q, Pan F, Qiu B, Tang B. Knockdown of KRT17 decreases osteosarcoma cell proliferation and the Warburg effect via the AKT/mTOR/HIF1α pathway. Oncol Rep 2020;44:103-14. [PMID: 32627037 DOI: 10.3892/or.2020.7611] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]